---
title: "Macquarie Raises BEONE MEDICINES  TP to HKD257, Reiterates Outperform Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292456571.md"
description: "Macquarie raised BEONE MEDICINES' target price to HKD257 and reiterated an Outperform rating, citing BRUKINSA's market leadership and improved operating margins. The broker increased earnings forecasts for 2026-2028 by 3-5%, driven by higher sales and success rates. Macquarie projects combined sales of key pipeline products to reach USD3.8 billion by 2037, exceeding market estimates."
datetime: "2026-07-13T08:20:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292456571.md)
  - [en](https://longbridge.com/en/news/292456571.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292456571.md)
generator: "portal-rs"
---

# Macquarie Raises BEONE MEDICINES  TP to HKD257, Reiterates Outperform Rating

Macquarie published a research report stating that BEONE MEDICINES (06160.HK) +2.500 (+1.362%) Short selling $126.97M; Ratio 29.643% 's "BRUKINSA" continues to lead the US CLL market, helping rapidly improve operating margin, which is expected to reach the low double-digit level in 4Q25. In addition, products including CDK4 inhibitors and GPC3x4-1BB bispecific antibodies are expected to provide upside potential. The broker currently forecasts combined sales of BCL2 inhibitor Beqalzi, CDK4 inhibitors and GPC3x4-1BB bispecific antibodies to reach USD3.8 billion in 2037, 23% higher than the market forecast of USD3.1 billion.

Macquarie raised the target price of BEONE MEDICINES (06160.HK) +2.500 (+1.362%) Short selling $126.97M; Ratio 29.643% by 5% to HKD257, while lifting the US stock target price of BeOne Medicines Ltd. (ONC.US) to USD426, and reiterated its Outperform rating. It also raised its earnings forecasts for 2026 to 2028 by 4%, 3% and 5%, respectively, mainly reflecting higher BRUKINSA sales and improved success rates following inclusion in 1L MCL. The broker currently forecasts BEONE MEDICINES' operating margin to rise from 11% in 2Q26 to 12% in 4Q26, and further to 18% and 24% in 2027 and 2028, respectively. (gc/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-13 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [MQG.AU](https://longbridge.com/en/quote/MQG.AU.md)
- [MQBKY.US](https://longbridge.com/en/quote/MQBKY.US.md)

## Related News & Research

- [How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval](https://longbridge.com/en/news/297146976.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)
- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program](https://longbridge.com/en/news/296513179.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [BeOne Medicines and partners renew Brukinsa access programme for CLL](https://longbridge.com/en/news/296331290.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**